Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: A randomized placebo-controlled trial

Digestive Diseases and Sciences

Volumn 56, Issue 7, 2011, Pages 2088-2097

  Smith, Jill P ^a   Bingaman, Sandra I ^a   Ruggiero, Francesca ^a   Mauger, David T ^a   Mukherjee, Aparna ^a   McGovern, Christopher O ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

IBD; Mucosal healing; Naltrexone; Opioids

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; CORTICOSTEROID; IMMUNOMODULATING AGENT; NALTREXONE; PLACEBO;

ABDOMINAL PAIN; AGED; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; COLONOSCOPY; CONSTIPATION; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EVENING DOSAGE; FATIGUE; FEMALE; FLATULENCE; HAIR LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSOMNIA; INTESTINE MUCOSA; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; VOMITING; WOUND HEALING;

ADULT; AGED; COLONOSCOPY; CROHN DISEASE; FATIGUE; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959725500     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1653-7     Document Type: Article

References (37)

1. Strober W, James SP. The immunopathogenesis of gastrointestinal and hepatobiliary diseases. JAMA. 1992;268:2910-2917.
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205. (Pubitemid 28307304)
3. Gurudu S, Fiocchi C, Katz JA. Inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2002;16:77-90.
4. Targan SR, Murphy LK. Clarifying the causes of Crohn's. Nat Med. 1995;1:1241-1243.
5. Kelly JK, Sutherland LR. The chronological sequence in the pathology of Crohn's disease. J Clin Gastroenterol. 1988;10:28-33. (Pubitemid 18062518)
6. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104: 465-483.
7. Bewtra M, Lewis JD. Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am. 2009;38:669-689.
8. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267. (Pubitemid 46175082)
9. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639-1641.
10. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936. (Pubitemid 351451967)
11. Pol O, Puig MM. Expression of opioid receptors during peripheral inflammation. Curr Top Med Chem. 2004;4:51-61. (Pubitemid 38842560)
12. Rogers TJ, Peterson PK. Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol. 2003;24:116-121. (Pubitemid 36263094)
13. Bryant HU, Bernton EW, Holaday JW. Immunosuppressive effects of chronic morphine treatment in mice. Life Sci. 1987;41:1731-1738.
14. Grimm MC, Ben Baruch A, Taub DD, Howard OM, Wang JM, Oppenheim JJ. Opiate inhibition of chemokine-induced chemotaxis. Ann N Y Acad Sci. 1998;840:9-20. (Pubitemid 28302032)
15. Janecka A, Fichna J, Janecki T. Opioid receptors and their ligands. Curr Top Med Chem. 2004;4:1-17. (Pubitemid 38842558)
16. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001;62:111-123. (Pubitemid 32195501)
17. Kamphuis S, Eriksson F, Kavelaars A, et al. Role of endogenous pro-enkephalin A-derived peptides in human T cell proliferation and monocyte IL-6 production. J Neuroimmunol. 1998;84:53-60. (Pubitemid 28210449)
18. Vujic V, Stanojevic S, Dimitrijevic M. Methionine-enkephalin stimulates hydrogen peroxide and nitric oxide production in rat peritoneal macrophages: interaction of mu, delta and kappa opioid receptors. Neuroimmunomodulation. 2004;11:392-403. (Pubitemid 39377729)
19. Peng X, Mosser DM, Adler MW, Rogers TJ, Meissler JJ Jr, Eisenstein TK. Morphine enhances interleukin-12 and the production of other pro-inflammatory cytokines in mouse peritoneal macrophages. J Leukoc Biol. 2000;68:723-728.
20. Hook S, Camberis M, Prout M, Le Gros G. Absence of preproenkephalin increases the threshold for T cell activation. J Neuroimmunol. 2003;140:61-68. (Pubitemid 36836090)
21. Zagon IS, McLaughlin PJ. Opioids and differentiation in human cancer cells. Neuropeptides. 2005;39:495-505. (Pubitemid 41443526)
22. Zagon IS, Jenkins JB, Sassani JW, et al. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat. Diabetes. 2002;51:3055-3062.
23. Matters GL, Harms JF, McGovern C, et al. The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicol. 2008;5:179-187. (Pubitemid 351882422)
24. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102:820-828. (Pubitemid 46496605)
25. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
26. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983-989.
27. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114:385-391. (Pubitemid 28539597)
28. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial study group. Gastroenterology. 1994;106:287-296.
29. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160-164.
30. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. (Pubitemid 34533555)
31. D'Haens G, van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999;116:1029-1034. (Pubitemid 29203012)
32. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442. (Pubitemid 43261469)
33. Dotan I, Rachmilewitz D, Schreiber S, et al. A randomised placebo- controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut. 2010;59:760-766.
34. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo- controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818. (Pubitemid 41242673)
35. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:1218-1224.
36. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population- based cohort. Gastroenterology. 2007;133:412-422. (Pubitemid 47187355)
37. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am. 2009;38:577-594.